FTSE China A50 Index Quarterly Review: Four Stocks Added, Effective Sep. 22, 2025China FinanceBeiGene, China Unicom, Index Funds, Stock Market, WuXi AppTec September 3, 2025
China’s Premier Signals a Massive Push for its Biopharma Industry: Here’s What You Need to KnowChina Finance Tech in ChinaAI, BeiGene, Changping Laboratory, Healthcare, Innovation, Li Qiang August 20, 2025
HHLR Q1 Snapshot: Portfolio Value Jumps, China Bets Get BiggerChina Finance Tech in ChinaAlibaba Group, Atour Group, Baidu, BeiGene, ECARX Holdings, Futu Holdings, Guangxi Yuchai International, Hillhouse Capital, Huazhu Group, Investment Trends, JD.com, Kanzhun Limited, KE Holdings, Legend Biotech, Li Auto, NetEase, PDD Holdings, Portfolio Analysis, Trip.com Group, Vipshop, WNS HLDGS LTD, ZTO Express May 16, 2025
STAR Market Pharma 2024 Report Card: Profit Growth for 53%, R&D Spend Hits ¥350M AverageChina Finance Tech in ChinaBeiGene, Biopharma, BioRay Pharmaceutical, EndoPuls Therapeutics, Jiangsu Jindiaok Biotechnology, Junshi Biosciences, Kexing Biopharm, Medicilon, MicroPort EP, Nansin Pharm, Notta & Belle, Profitability, R&D, RemeGen, SinoCellTech, STAR Market, Sunny Pharmatech, Sunshine Guojian Pharmaceutical, Tinavi Medical Technologies, United Imaging Healthcare, Xiangyu Medical, Zhixiang Bio May 6, 2025
